

# A founder heterozygous mutation in methyl-CpG binding domain protein 4 (MBD4) prevalent among Israeli Christian Arabs predisposes to increased mutagenesis

## Authors

---

Gal Dadi,<sup>1</sup> Sara Rosen,<sup>1</sup> Hadas Naor,<sup>1</sup> Elias Hellou,<sup>2,3</sup> Noa Chapal-Ilani,<sup>1</sup> Tal Bacharach,<sup>1</sup> Nathali Kaushansky<sup>1</sup> and Liran I. Shlush<sup>1</sup>

<sup>1</sup>Weizmann Institute of Science, Rehovot, Israel; <sup>2</sup>Mayo Clinic Rochester, Rochester, MN, USA and <sup>3</sup>Nazareth Hospital EMMS, Nazareth, Israel

Correspondence:

G. DADI - [galdadi@gmail.com](mailto:galdadi@gmail.com)

<https://doi.org/10.3324/haematol.2025.287690>

Received: February 26, 2025.


Accepted: August 22, 2025.

Early view: September 4, 2025.

©2026 Ferrata Storti Foundation


Published under a CC BY-NC license 

A




B

SBS96 % of Total Exposure by Group



C

SBS96 % of Total Exposure by Group



Supplementary Figure 1. Somatic mutations, age correlations, and CpG-biased mutational signatures in  $MBD4$ -deficient individuals. (A) Correlation between age and total number of somatic mutations in peripheral blood in three cohorts:  $MBD4$  c.612\_615del heterozygous carriers (left), in-house  $MBD4^{+/+}$  controls (middle), and TCGA blood-derived normals (right). No significant correlation was observed ( $MBD4$  c.612\_615del heterozygous carriers: Pearson  $r = -0.5$ ,  $p = 0.17$ ;  $MBD4^{+/+}$ :  $r = 0$ ,  $p = 0.99$ ; TCGA:  $r = -0.06$ ,  $p = 0.75$ ), suggesting age alone does not account for the increased mutation burden in  $MBD4$  c.612\_615del heterozygous carriers. Each point represents one donor; TCGA samples are color-coded by tumor type. (B) SBS96 mutational signature contribution in leukemic samples from the  $MBD4$  biallelic c.612\_615del patient compared to 11 AML samples from the Beat AML cohort (\*\*\*)  $p < 0.001$ , Wilcoxon rank-sum test). (C) SBS96 signature proportion in  $MBD4$  c.612\_615del heterozygous carriers ( $n = 9$ ), in-house  $MBD4^{+/+}$  healthy donors ( $n = 19$ ), and TCGA blood-derived normal samples ( $n = 36$ ) from peripheral blood, showing significantly increased SBS96 contribution in  $MBD4$  c.612\_615del heterozygous carriers compared to both controls (\*\*\*)  $p < 0.001$ , Wilcoxon rank-sum test). Abbreviations: AML – Acute myeloid leukemia; SBS, Single Base Substitution; TCGA- The Cancer Genome Atlas; WT- wild type.